73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir

BACKGROUND: Remdesivir (RDV), a RNA polymerase inhibitor with potent in vitro activity against SARS-CoV-2, is the only treatment with demonstrated efficacy in shortening the duration of COVID-19. Here we report regional differences in clinical outcomes of severe COVID-19 patients treated with RDV, a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Open Forum Infect Dis
Asıl Yazarlar: Diaz, George, Arribas, Jose Ramon, Robinson, Philip A, Cattelan, Anna Maria, Tashima, Karen T, Tsang, Owen Tak-Yin, Chen, Yao-Shen, SenGupta, Devi, Vendrame, Elena, Blair, Christiana, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Chin, Bum Sik, Spinner, Christoph, Criner, Gerard J, Muñoz, Jose, Lye, David Chien Boon, Gottlieb, Robert L
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Poster Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7778124/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.383
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller